COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

We are proud to be recognized on the Deloitte 2020 Technology Fast 500 list
We are proud to be recognized on the Deloitte 2020 Technology Fast 500 list
BDSI
BDSI
INSPIRING SOLUTIONS FOR BETTER HEALTH
BDSI advances novel therapies designed to improve the lives of people living with serious and debilitating chronic conditions
Thomas Smith, MD, Chief Medical Officer at BDSI, interviews healthcare experts on what patients living with chronic pain experience.

Listening to healthcare practitioners helps us understand how we can deliver meaningful solutions to the patient community. We are dedicated to the constant pursuit of improving patients’ lives.

Watch now

Purpose

BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions.

Learn more

Patients

BDSI subscribes to a patients-first philosophy. We are a dynamic team driven by the knowledge that the work we do can have a positive impact on patients, their caretakers, and loved ones.

Learn more

Products

BDSI offers a diverse portfolio of solutions for the treatment of serious and debilitating chronic conditions, including unique therapeutic innovations like a buccal film technology designed to help optimize drug delivery.

Learn more

Recent BDSI News

May 6, 2021

Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery

Read more
April 20, 2021

RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021

Read more
March 10, 2021

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
May 10, 2021BDSI $3.18/ - 0%
Data provided by Nasdaq. Minimum 15 minutes delayed.